Is CRISPR Therapeutics AG (CRSP) a Buy, Sell, or Hold?
NASDAQ : CRSP
CRISPR Therapeutics AG — Institutional Ownership
$52.06 USD
-$1.01 (-1.9%)
- Volume
- 290.34K
- Average Volume
- 1.73M
- Market Capitalization
- $5.02B
- P/E Ratio
- -10.94
- Dividend Yield
- 0.00%
- Price Target
- $76.00
- Year High
- $78.48
- Year Low
- $44.12
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $17.85
Institutional Ownership Summary
Institutional Ownership %
4.69%
Investors Holding
195
change: -329.0 | last: 524
Increased Positions
70
change: -185.0 | last: 255
Reduced Positions
50
change: -72.0 | last: 122
New Positions
30
change: -48.0 | last: 78
Sold Positions
339
change: 262.0 | last: 77
Total Calls
135.4K
Total Puts
127.9K
Put-Call Ratio
0.94
change: 10.6766 | last: 0.8378
Total Invested
244.02M
Beneficial Ownership Filings
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2026-05-15 | ORBIS INVESTMENT MANAGEMENT LTD | 6.09M | 6.30% |
| 2026-05-14 | Capital World Investors | 4.93M | 5.10% |
| 2026-04-30 | ARK Investment Management LLC | 11.31M | 11.79% |
| 2026-02-17 | ORBIS INVESTMENT MANAGEMENT LTD | 5.93M | 6.20% |
| 2026-02-05 | Capital International Investors | 1.19M | 1.20% |
| 2025-11-14 | ORBIS INVESTMENT MANAGEMENT LTD | 4.97M | 5.50% |
| 2025-11-04 | ARK Investment Management LLC | 9.79M | 10.76% |
| 2025-07-17 | BlackRock, Inc. | 5.93M | 6.90% |
| 2025-05-14 | ARK Investment Management LLC | 10.17M | 11.85% |
| 2025-05-13 | Capital International Investors | 6.33M | 7.40% |
| 2025-02-14 | ARK Investment Management LLC | 8.97M | 10.51% |
| 2025-01-10 | ARK Investment Management LLC | 7.5M | 8.80% |
| 2023-02-13 | 95-1411037 | 13.0 | 7.10% |
| 2022-02-14 | Nikko Asset Management Americas, Inc. | 4.32M | 5.64% |
| 2022-02-11 | 95-1411037 | 13.0 | 4.80% |
| 2022-02-09 | ARK Investment Management LLC | 9.09M | 11.88% |
| 2022-02-04 | Sumitomo Mitsui Trust Holdings, Inc. (“SMTH”) | 4.32M | 5.64% |
| 2022-02-04 | Nikko Asset Management Co., Ltd. (“NAM”) | 4.32M | 5.64% |
| 2021-09-10 | ARK Investment Management LLC | 7.64M | 10.03% |
| 2021-08-10 | 95-1411037 | 13.0 | 5.60% |
| 2021-02-16 | Versant Affiliates Fund V, L.P. | 34977.0 | 0.00% |
| 2021-02-16 | ARK Investment Management LLC | 10.41M | 14.62% |
| 2021-02-16 | Versant Venture Capital IV, L.P. | 1.34M | 1.90% |
| 2021-02-16 | Versant Side Fund IV, L.P. | 7922.0 | 0.00% |
| 2021-02-16 | Versant Ventures IV, LLC | 1.34M | 1.90% |
| 2021-02-16 | Versant Venture Capital V, L.P. | 1.19M | 1.70% |
| 2021-02-16 | Versant Ophthalmic Affiliates Fund I, L.P. | 38772.0 | 0.10% |
| 2021-02-16 | Versant Ventures V, LLC | 1.27M | 1.80% |
| 2021-02-16 | Versant Venture Capital V (Canada) LP | 90730.0 | 0.10% |
| 2021-02-16 | GP-GP | 90730.0 | 0.10% |
| 2021-02-16 | Versant Ventures V (Canada), L.P. | 90730.0 | 0.10% |
| 2021-02-16 | Versant Venture Management, LLC | 339.83K | 0.50% |
| 2021-02-16 | 95-1411037 | 13.0 | 10.70% |
| 2021-02-11 | Nikko Asset Management Americas, Inc. | 3.84M | 5.39% |
| 2021-02-05 | Nikko Asset Management Co., Ltd. (“NAM”) | 3.84M | 5.39% |
| 2021-02-05 | Sumitomo Mitsui Trust Holdings, Inc. (“SMTH”) | 3.84M | 5.39% |
| 2020-09-18 | Versant Venture Capital IV, L.P. | 2.07M | 3.00% |
| 2020-09-18 | Versant Affiliates Fund V, L.P. | 34977.0 | 0.00% |
| 2020-09-18 | Versant Venture Capital V, L.P. | 1.19M | 1.70% |
| 2020-09-18 | Versant Ventures IV, LLC | 2.09M | 3.00% |
| 2020-09-18 | Versant Side Fund IV, L.P. | 12303.0 | 0.00% |
| 2020-09-18 | Versant Venture Management, LLC | 521.22K | 0.70% |
| 2020-09-18 | Versant Ventures V (Canada), L.P. | 90730.0 | 0.10% |
| 2020-09-18 | GP-GP | 90730.0 | 0.10% |
| 2020-09-18 | Versant Venture Capital V (Canada), L.P. | 90730.0 | 0.10% |
| 2020-09-18 | Versant Ventures V, LLC | 1.27M | 1.80% |
| 2020-09-18 | Versant Ophthalmic Affiliates Fund I, L.P. | 38772.0 | 0.10% |
| 2020-09-10 | 95-1411037 | 13.0 | 10.70% |
| 2020-09-10 | 95-1411037 | 13.0 | 10.70% |
| 2020-02-13 | Vertex Pharmaceuticals Incorporated (“Vertex US”) | 2.69M | 4.40% |
| 2020-02-13 | Vertex Pharmaceuticals (Europe) Limited (“Vertex Europe”) | 2.69M | 4.40% |
| 2020-02-12 | Nikko Asset Management Americas, Inc. | 3.05M | 5.08% |
| 2020-02-12 | Nikko Asset Management Co., Ltd. (“NAM”) | 3.05M | 5.08% |
| 2020-02-12 | Sumitomo Mitsui Trust Holdings, Inc. (“SMTH”) | 3.05M | 5.08% |
| 2018-02-08 | CELGENE ALPINE INVESTMENT CO. III, LLC | 2.8M | 6.10% |
| 2018-02-08 | CELGENE CORPORATION | 2.8M | 6.10% |
| 2017-12-26 | CELGENE ALPINE INVESTMENT CO. III, LLC | 3.31M | 8.10% |
| 2017-12-26 | CELGENE CORPORATION | 3.31M | 8.10% |
| 2017-12-06 | CELGENE ALPINE INVESTMENT CO. III, LLC | 3.72M | 9.10% |
| 2017-12-06 | CELGENE CORPORATION | 3.72M | 9.10% |
| 2017-08-14 | Abingworth Bioventures VI, LP 98-1059389 | 2.16M | 5.30% |
| 2017-08-14 | Abingworth LLP 98-051-8585 | 2.16M | 5.30% |
| 2017-02-13 | Vertex Pharmaceuticals Incorporated ("Vertex US") | 3.19M | 8.00% |
| 2017-02-13 | Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe") | 3.19M | 8.00% |
| 2017-02-06 | Ravi Viswanathan | 3.22M | 8.10% |
| 2017-02-06 | New Enterprise Associates 15, L.P. | 3.22M | 8.10% |
| 2017-02-06 | Scott D. Sandell | 3.22M | 8.10% |
| 2017-02-06 | Jon M. Sakoda | 3.22M | 8.10% |
| 2017-02-06 | David M. Mott | 3.22M | 8.10% |
| 2017-02-06 | Joshua Makower | 3.22M | 8.10% |
| 2017-02-06 | Anthony A. Florence, Jr. | 3.22M | 8.10% |
| 2017-02-06 | Forest Baskett | 3.22M | 8.10% |
| 2017-02-06 | Peter J. Barris | 3.22M | 8.10% |
| 2017-02-06 | NEA 15 GP, LLC | 3.22M | 8.10% |
| 2017-02-06 | NEA Partners 15, L.P. | 3.22M | 8.10% |
| 2017-02-06 | Peter W. Sonsini | 3.22M | 8.10% |
| 2016-11-03 | Abingworth LLP 98-051-8585 | 2.6M | 6.60% |
| 2016-11-03 | Abingworth Bioventures VI, LP 98-1059389 | 2.6M | 6.60% |
| 2016-10-31 | CELGENE ALPINE INVESTMENT CO. III, LLC | 4.83M | 12.30% |
| 2016-10-31 | CELGENE CORPORATION | 4.83M | 12.30% |
CRSP Enterprise Value History
Annual
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2025-12-31 | $52.44 | 89.93M | $4.72B | $355.19M | $394.91M | $4.76B |
| 2024-12-31 | $39.36 | 84.36M | $3.32B | $298.26M | $223.69M | $3.25B |
| 2023-12-31 | $62.60 | 79.22M | $4.96B | $389.48M | $238.63M | $4.81B |
| 2022-12-31 | $40.65 | 77.75M | $3.16B | $211.88M | $244.02M | $3.19B |
| 2021-12-31 | $75.78 | 75.95M | $5.76B | $923.03M | $225.03M | $5.06B |
| 2020-12-31 | $153.11 | 65.95M | $10.1B | $1.17B | $61.43M | $8.99B |
| 2019-12-31 | $60.91 | 54.39M | $3.31B | $943.77M | $52.54M | $2.42B |
| 2018-12-31 | $28.57 | 47.96M | $1.37B | $456.65M | -$ | $913.56M |
| 2017-12-31 | $23.48 | 39.97M | $938.61M | $239.76M | -$ | $698.85M |
| 2016-12-31 | $20.26 | 12.26M | $248.34M | $315.52M | -$ | -$67.18M |
Quarterly
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-06-30 | $54.54 | 96.51M | $5.26B | $291.34M | $783.75M | $5.76B |
| 2026-03-31 | $47.57 | 96.05M | $4.57B | $423.31M | $787.64M | $4.93B |
| 2025-12-31 | $52.44 | 89.93M | $4.72B | $355.19M | $394.91M | $4.76B |
| 2025-09-30 | $64.81 | 91.31M | $5.92B | $290.01M | $403.79M | $6.03B |
| 2025-06-30 | $48.64 | 87.07M | $4.24B | $197.13M | $215.45M | $4.25B |
| 2025-03-31 | $34.03 | 85.94M | $2.92B | $235.18M | $219.36M | $2.91B |
| 2024-12-31 | $39.36 | 85.46M | $3.36B | $298.26M | $223.69M | $3.29B |
| 2024-09-30 | $46.98 | 85.24M | $4B | $225.67M | $227.54M | $4.01B |
| 2024-06-30 | $53.95 | 84.92M | $4.58B | $484.47M | $231.3M | $4.33B |
| 2024-03-31 | $68.18 | 81.79M | $5.58B | $707.43M | $234.93M | $5.1B |
| 2023-12-31 | $62.60 | 79.69M | $4.99B | $389.48M | $238.63M | $4.84B |
| 2023-09-30 | $45.39 | 79.41M | $3.6B | $527.76M | $241.59M | $3.32B |